Pages that link to "Q41093141"
Jump to navigation
Jump to search
The following pages link to Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer (Q41093141):
Displaying 12 items.
- Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer (Q50113702) (← links)
- The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview (Q57470611) (← links)
- Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response (Q61805942) (← links)
- Axl signaling is an important mediator of tumor angiogenesis (Q64097927) (← links)
- NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway (Q90798961) (← links)
- Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma (Q91588160) (← links)
- Does Axl have potential as a therapeutic target in pancreatic cancer? (Q91659317) (← links)
- Soluble AXL as a marker of disease progression and survival in melanoma (Q92517975) (← links)
- Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells (Q92890237) (← links)
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer (Q93380660) (← links)
- Regulation of efferocytosis as a novel cancer therapy (Q94547253) (← links)
- Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells (Q97692527) (← links)